newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Announces Changes to Board of Directors

  • MapLight Therapeutics announced the election of Martin Babler and Troy Cox to its Board of Directors following the June 23, 2026 Annual Meeting of Stockholders.
  • Babler & Cox succeed Robert Malenka & Jim Trenkle, who concluded their service on the Board.
  • Babler was appointed to the Audit Committee.
  • Cox was appointed Chair of the Nominating and Corporate Governance Committee.
  • Babler currently serves as President, CEO, & Chairman of Alumis Inc. & previously led Principia Biopharma & Talima Therapeutics.
  • Cox previously served as President & CEO of Foundation Medicine & held senior leadership roles at Genentech, UCB BioPharmaceuticals, Sanofi-Aventis, & Schering-Plough.
  • MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.
  • The company utilizes a discovery platform to identify neural circuits causally linked to disease for therapeutic modulation.